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Abstract
Asthma and chronic obstructive pulmonary disease (COPD) are thought to share a genetic 
background (“Dutch hypothesis”).
We investigated whether asthma and COPD have common underlying genetic factors, performing 
genome-wide association studies for both asthma and COPD and combining the results in meta-
analyses.
Three loci showed potential involvement in both diseases: chr2p24.3, chr5q23.1 and chr13q14.2, 
containing DDX1, COMMD10 (both participating in the NFκβ pathway) and GNG5P5, 
respectively. SNP rs9534578 in GNG5P5 reached genome-wide significance after first stage 
replication (p=9.96·*10−9). The second stage replication in seven independent cohorts provided no 
significant replication. eQTL analysis in blood and lung on the top 20 associated SNPs identified 
two SNPs in COMMD10 influencing gene expression.
Inflammatory processes differ in asthma and COPD and are mediated by NFκβ, which could be 
driven by the same underlying genes, COMMD10 and DDX1. None of the SNPs reached genome-
wide significance. Our eQTL studies support a functional role of two COMMD10 SNPs, since 
they influence gene expression in both blood cells and lung tissue. Our findings either suggest that 
there is no common genetic component in asthma and COPD or, alternatively, different 
environmental factors, like lifestyle and occupation in different countries and continents may have 
obscured the genetic common contribution.
Introduction
Asthma and Chronic Obstructive Pulmonary Disease (COPD) are two common respiratory 
diseases. Their estimated prevalence ranges from approximately 1% to 18% in different 
countries.[1–3] Both diseases may lead to airway obstruction, which is reversible in asthma 
in contrast to COPD. However, the diagnosis cannot rely on reversibility, as it can disappear 
with asthma progression, making asthma and COPD harder to distinguish. The immune 
mechanisms underlying the two diseases are thought to be very different, but similarities in 
inflammatory processes have recently been reported in both disease entities.[4] Classically 
inflammation in asthma is represented by elevated numbers of CD4+ lymphocytes and 
eosinophils, while in COPD there are CD8+ lymphocytes, macrophages and neutrophils.[5] 
However, severe asthma can be accompanied by neutrophilia [6] and COPD exacerbation by 
eosinophilia.[7]
Over fifty years ago, the so called 'Dutch hypothesis' was formulated by Orie and colleagues 
[8] stating that asthma and COPD are two features of one disease entity, referred to as 
chronic non-specific lung disease (CNSLD). CNSLD was defined to result from the 
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interplay of endogenous factors like genetic predisposition, and exogenous factors like viral 
infections, air pollution, tobacco smoking and allergen exposures. The timing of this 
interplay would then determine which clinical syndrome one developed during a lifetime, 
i.e. asthma, or COPD, or features of both asthma and COPD.
So far this hypothesis has neither been confirmed nor refuted completely, [9] but several 
common environmental exposures have been unequivocally identified as shared risk factors 
for both asthma and COPD, e.g. maternal smoking during pregnancy, air pollution and 
active smoking.[10] Genetic factors have been associated with either asthma or COPD using 
linkage,[11–15] candidate gene [16–19] and genome-wide association studies (GWAS).
[20,21] These studies elucidated genetic factors unique either to asthma or COPD, but 
additionally potentially shared genetic risk factors including TGFB1, TNFA, GSTP1, IL13 
[22] and SERPINE2 [23]. ADAM33 has been linked to the presence of asthma [24], COPD 
and accelerated lung function decline in the general population and in asthma [25,25], 
suggesting common underlying genetic factors for both onset and course of asthma and 
COPD.[26] So far, hypothesis free GWAS studies aiming to identify novel genes underlying 
both asthma and COPD in the same source population are lacking. The aim of our study was 
to identify shared genetic risk factors for asthma and COPD using an unbiased GWAS 
approach. We first performed a GWAS on asthma and COPD separately using individuals of 




For the identification phase, subjects were recruited as participants of the following asthma 
and COPD cohorts:
1. The Dutch Asthma GWAS (DAG) Study: a cohort screened for genetic studies, 
characterized by the presence of a doctor diagnosis of asthma and bronchial 
hyperresponsiveness.
2. The NELSON cohort study [42]: a population-based cohort screening for lung 
cancer, including current or ex-smokers with at least 20 pack-years. To increase 
power of the COPD set, blood bank controls from Amsterdam and Utrecht without 
clinical data except for age (range 18–65), were added.
The results of the GWAS were meta-analyzed (meta-analysis1). A meta-analysis is a method 
to combine results from different studies, with the aim to more powerfully estimate the true 
effect size as opposed to a less precise effect size derived in a single study. A weighted 
average of that common effect size is the output of a meta-analysis. The weighting is related 
to sample sizes within the individual studies.
For the 1st replication phase (meta-analysis2) participants of the LifeLines cohort study 
(LifeLines1) were studied.
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In the 2nd replication phase (meta-analyses 3–9) the top 20 single nucleotide polymorphisms 
(SNPs) were evaluated in participants of an independent sample of LifeLines (LifeLines2), 
and the SAPALDIA, RS-I, RS-II, RS-III, MESA, and ARIC cohorts.
There were no overlapping subjects in any cohorts used. All participants signed informed 
consent; studies were approved by institutional ethics committees. Detailed information and 
characteristics of the study populations are shown in Supplementary Appendix (Table S1 
and Text S1).
Asthma and COPD phenotype definition
In all cohorts, asthma was defined as having a doctor diagnosis of asthma ever, or use of 
asthma medication (beta-agonists, steroids, anticholinergics, cromoglycate, montelukast, 
theophyllines) while having 2 or more of the following symptoms: wheeze without a cold, 
an attack of breathlessness while resting, waking up with an attack of breathlessness, ever. 
Controls were defined as not having asthma.
In all cohorts, COPD was defined as a pre-bronchodilator FEV1/FVC<0.7 (asthma cases 
were excluded), and controls (except for blood bank controls) were defined as having an 
FEV1/FVC>0.7 and FEV1>90% predicted.
Genotyping, quality control and imputation
All cohorts were genotyped with Illumina arrays with different SNP content. Genotypes 
were called and standard quality control was performed (see supplement).
Study design and statistical analyses
The analytic work flow is shown in Figure 1. Genome-wide associations on asthma 
(2,004,043 SNPs) and COPD (1,872,289 SNPs) were performed using χ2- test using a 
genetic additive model (0, 1, and 2).
Next, results were combined in a meta-analysis using 1,811,026 SNPs shared between the 
asthma and COPD datasets (meta-analysis1). 2,048 SNPs showing p<0.001 were selected 
for in silico replication in a second set of asthma and COPD case-control groups derived 
from the LifeLines cohort (LifeLines1). These markers were analyzed with χ2- tests and then 
combined in a second directional meta-analysis (meta-analysis2). The top 20 SNPs with 
p≤0.001 from meta-analysis2 were investigated in the second stage replication consisting of 
7 meta-analyses in LifeLines2, SAPALDIA, RS-I, RS-II, RS-III, MESA, and ARIC (for 
cohort description see Text S1).
In the meta-analyses (apart from LifeLines 2) genetic associations with asthma and COPD 
were tested using logistic regression. Models were controlled for pack-years smoking, study 
area and principal components capturing inter-European population structure. Results were 
then combined using the Fisher’s method. SNPs with p<0.05 in meta-analysis2 are shown in 
Table S4.
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eQTL mapping in blood and lung tissue
eQTL (expression quantitative trait locus) mapping in blood was performed as described 
previously by Fehrmann et al.[27] Briefly, each probe on the expression chip was mapped 
and correlated with SNPs in the vicinity of 250kb. Principal component analysis was applied 
to the data prior to the analysis to ensure that signals detected as eQTLs are not due to e.g. 
batch effects. Analysis involved non-parametric Spearman's rank correlation test. Because 
two different expression chips were used, when probes were present on both, the final result 
came from meta-analysis. False discovery rate was applied to account for multiple testing.
eQTL-mapping in lung tissue was performed as described previously in 3 independent data 
sets in a collaboration between University of Groningen (Groningen, The Netherlands), 
Laval University (Quebec City, Canada) and British Columbia (Vancouver, Canada).[43] 
Briefly lung specimens were obtained from patients undergoing lung resection surgery at the 
three participating sites. Whole-genome gene expression and genotyping data were obtained 
from these specimens. Gene expression profiling was performed using an Affymetrix 
custom array (GEO platform GPL10379) testing 51,627 non-control probe sets and 
normalized using RMA.[44] Genotyping was performed using the Illumina Human1M-Duo 
BeadChip array. Following standard microarray and genotyping quality controls, 1111 
patients were available for eQTL analyses. Cis- and trans-acting eQTLs were calculated as 
previously.[45]
Network analysis
Gene network was constructed using GeneMANIA.[46] The gene set resulting from this 
approach was investigated with GATHER [47] to identify enriched pathways.
More details are presented in the supplement.
Results
Genome-wide association and meta-analyses
GWAS were performed on both asthma (921 cases, 3,246 controls) and COPD (1,030 cases, 
1,808 controls). Genomic inflation factors (λ) equaled 1.01 for both asthma and COPD, 
indicating no population stratification (Figure S1). Individual p-values and odds ratios (ORs) 
were combined in a directional meta-analysis using a fixed-effects model (meta-analysis1, 
Figure 1; this data is publicly available at The European Genome-phenome Archive (EGA), 
accession number EGAS00000000130). All 2,048 SNPs with p≤0.001 were selected for a 
first replication analysis in asthma (534 cases and 2,568 controls) and COPD (711 cases and 
1,854 controls) cohorts separately. Subsequently results were combined in a meta-analysis 
(meta-analysis2, Figure 1).
Twenty SNPs replicated at p<0.001 (Table 2) in the combined meta-analysis1 and meta-
analysis2, one SNP reached genome wide significance.
Nineteen of these 20 SNPs map to three genomic locations: 2p24.3, 5q23.1, and 13q14.2 
(Table S2).
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The chromosome 2p24.3 locus spans ~380 kb and contains genes encoding functional units, 
like processed transcripts, pseudogenes and RNA genes (Figure 2). The nearest gene with a 
known function, DEAD-box polypeptide 1 (DDX1), is ~139kb away from the top associated 
2p24.3 SNP rs1477253. The locus on chromosome 5 is ~328 kb and contains a single gene: 
COMM domain containing 10 (COMMD10) (Figure 2). The locus on chromosome 13 spans 
~320 kb and only contains a pseudogene: guanine nucleotide binding protein (G protein), 
gamma 5 pseudogene 5 (GNG5P5) (Figure 2). SNP rs9534578 in GNG5P5 reached 
genome-wide significance (p = 9.96*10−9).
Replication phase 2 of top 20 SNPs
The top 20 markers from the combined analysis were further evaluated in an independent 
sample of the LifeLines cohort (LifeLines2; asthma: 317 cases and 2,363 controls; COPD: 
601 cases and 1,868 controls) and the SAPALDIA cohort (asthma: 461 cases, 522 controls, 
COPD: 118 cases, 656 controls), RS-I (asthma: 126 cases, 4,241 controls, COPD: 229 cases, 
781 controls), RS-II (asthma: 58 cases, 1,584 controls, COPD: 186 cases, 783 controls), RS-
III (asthma: 71 cases, 1,714 controls, COPD: 79 cases, 824 controls), MESA (asthma: 267 
cases, 2,381 controls, COPD: 104 cases, 979 controls, COPD), ARIC (Asthma: 453 cases, 
9,203 controls, COPD: 915 cases, 6,610 controls). None of the SNPs replicated at a nominal 
p-value <0.05. Meta-analysis of all cohorts together did not result in genome-wide 
significant associations (Table 2 and Forest plots of the meta-analyses of the three top SNPs 
in Figure 3).
SNPs in the DDX1 and COMMD10 locus were associated with both asthma and COPD 
(Table S3). The meta-analysis results of the GNG5P5 locus were driven by the association 
with the COPD phenotype, since non of the GNG5P5 SNPs were significantly associated 
with the asthma phenotype.
eQTL analysis of top 20 SNPs
Three of the top 20 SNPs from the combined analysis showed a cis-eQTL effect, when 
correlating the genotypes with gene expression levels in 1,469 peripheral blood 
mononuclear cell samples with both GWAS and genome-wide gene expression data 
available.[27] The three SNPs were located in COMMD10. Figure 4 shows that the risk 
allele (G) (and rs10043228 (T) which is in perfect LD (r2=1) with rs10036292, increased 
COMMD10 expression levels in blood mononuclear cells, with similar findings in lung 
tissue.
Network analysis
The genes found were investigated with GeneMANIA which does not support pseudogenes. 
Hence we queried only COMMD10 and DDX1. This gene enrichment approach resulted in 
a set of genes, two genes (RAD50 and MRE11A) being involved in regulation of mitotic 
recombination (Bayes factor 11, p<0.0001) and telomere maintenance (Bayes factor 6, 
p<0.0001), possibly implicating COPD as a disease of rapidly aging lungs. [28] Another 
gene (BICD1) involved in telomere maintenance was previously reported in emphysema.
[29]
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Moreover, products of DDX1 and COMMD10 interact with NFκβ2. COMMD10 has a 
direct interaction, while DDX1 interacts with RELA and RELB, known to interact directly 
with NFκβ2 and to function in the same pathway (Figure 5).
Discussion
This is the first investigation of shared genetics for asthma and COPD in a hypothesis-free 
manner using a genome-wide screening in asthma and COPD in large population-based 
cohorts. We report three novel loci as potentially shared genetic factors between asthma and 
COPD, none reaching genome-wide significance in the discovery set or seven replication 
cohorts. None of these three loci were previously reported to be associated with either 
asthma or COPD. However, DDX1 locus was reported in a recently published meta-analysis 
of lung function [30], with a p-value of 9*10−6. The T allele of rs2544527 in DDX was 
associated with lower lung function and in our study with a risk for both asthma and COPD.
The shared 5q23.1 risk locus contains the COMMD10 gene. COMMD10 is a member of 
COMM domain containing proteins [31] with a largely unknown function. COMMD10 has 
been shown to form a complex with COMMD1, another member of this family of proteins, 
which regulates copper metabolism and sodium uptake and inhibits NFκβ activation.[32] 
Copper and sodium levels are inversely regulated, i.e. when copper levels increase, sodium 
import in cells is inhibited and vice versa. Both ion levels can be regulated by COMMD1, 
with sodium control mediated through epithelial sodium channels (ENaCs) that are 
abundantly present in lung epithelial cells.[33] Sodium is crucial for maintaining a fluidic 
layer in the alveolar part of the lungs and ENaCs play a crucial role in this process.[34] It is 
tempting to speculate that COMMD10 is involved in this maintenance either through 
interaction with COMMD1, or independently by displaying similar functions as COMMD1. 
Also, its function in inhibition of NFκβ activation could play a role in regulating 
inflammatory processes in airways diseases. Our eQTL studies support a functional role of 
COMMD10, since we established that two SNPs in the COMMD10 region influence 
expression of this gene in both blood cells and lung tissue.
The 13q14.2 locus contains the guanine nucleotide binding protein (G protein), gamma 5 
pseudogene 5 (GNG5P5). Poliseno et al recently showed that pseudogenes can have a 
pronounced role in regulation of their putative transcripts by competing in non-coding RNA 
binding.[35] It needs to be tested whether GNG5P5 can affect GNG5 levels, but it is 
interesting to note that the pseudogene is processed and has a transcript 
(ENST00000420444). The biological consequence of a change in GNG5 levels in relation to 
asthma and COPD pathology is unclear but it is well established that G proteins play a 
crucial role in signal transduction from cell surface to its interior. It is also known that G-
protein coupled receptors (GPCRs) are involved in asthma and more generally are a target of 
many of the currently used asthma drugs.[36]
A third locus on 2p24.3 is bordered by the DDX1 gene, encoding DEAD-box protein 1, 
RNA helicase I, and the MYCN genes whereas the locus itself contains non-protein coding 
genes including lincRNAs, ncRNAs, pseudogenes, processed transcripts and one newly 
discovered, protein-coding gene. Theoretically, any of these could be involved in asthma 
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and COPD, hindering interpretation of our findings. However, the regional association plot 
(Figure 2) shows that the signal is mostly confined to AC008278.3 and AC008271.1. 
Further refinement of the region and functional assessment of the associated variants could 
help to potentially pin-point the actual causal gene. DDX1 is a plausible candidate for both 
asthma and COPD since it interacts with RELA, one of NFκβ subunits, upon which it acts as 
a co-activator of NFκβ-mediated transcription.[37] Since this is a central and common 
pathway of inflammation present in the airways of both asthma and COPD, this may signify 
a unifying underlying mechanism of both disease entities. Further studies are needed to 
confirm this hypothesis.
The strengths of our study are the data quality of the cohorts involved, the design of the 
study and the analysis strategy of the discovery and replication phases. There are some 
limitations to our study as well. We found no overall replication in 6 out of 8 replication 
cohorts. One explanation for the lack of replication might be the differences in asthma and 
COPD patients in the replication cohorts compared with the identification cohort. For 
instance there was a somewhat lower prevalence of asthma in LifeLines2 (7.5% versus 8.5% 
in LifeLines1) due to the average older age of the subjects included in LifeLines2. This 
could reflect a cohort effect or some asthma remission at elderly ages.[38] Furthermore, 
most studies used an asthma definition of self-reported asthma diagnosis. Self-reported 
asthma has led to firm GWAS findings in the GABRIEL study.[39] However, it cannot be 
excluded that our asthmatic groups consisted in part of individuals diagnosed with asthma in 
childhood, who now are in complete remission. The GABRIEL cohort studies [39] 
suggested that the genetic background of early onset and adult-onset asthma is different. It 
would be of interest to assess whether COPD would have more overlap in genetic 
background with either childhood-onset than adult-onset asthma. A previous study from our 
group (48) showed overlap between candidate genes for COPD and early childhood wheeze 
and lower lung function, suggesting there is some overlap in genetic background in early 
childhood characteristics. This clearly needs further study, since we could not analyze this 
adequately in our cohort, where the prevalence of childhood asthma was 82% in our 
identification cohort and 41 in the verification cohort. Similarly, the diagnosis of COPD was 
based on lung function only, and this could have led to inclusion of different types of COPD 
in the various replication cohorts. For instance the prevalence of never smokers was 41% in 
SAPALDIA, whereas this was 0% in the identification and LifeLines 1 and 2 cohorts and 
ranging from 10–24% in the other cohorts. Furthermore some cohorts were of older age (e.g. 
mean age around 65 years in RS-I and RS-II and this may have led to inclusion of elderly 
asthmatics in the COPD group, since significant persistent airway obstruction may occur in 
asthma with ageing.[40] This may reflect an important limitation common to most GWAS, 
i.e. the heterogeneity of the phenotypes assessed, and heterogeneity between discovery and 
replication samples. Table S3 shows the heterogeneity per meta-analysis performed, i.e. for 
each asthma-COPD meta-analysis. It differs substantially and due to specificity of the study 
we could not account for the heterogeneity between meta-analyses. We did not find as prime 
hits a gene that was associated with asthma and with COPD previously. For instance 
ADAM33 was not significantly associated with either asthma or COPD or represented in 
their overlap. This may either be due to the fact that not all SNPs were captured in the 
GWAS analyses, or that ADAM33 was only found by positionally cloning when 
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hyperresponsiveness was present in asthmatics (49). The latter was not a prerequisite in our 
asthma definition, just as in other GWAS studies, where ADAM33 was also not found as a 
significant gene associated with asthma.
Do our findings then refute the Dutch hypothesis? This hypothesis states that both genetic 
and environmental factors contribute to the phenotypic outcome, and that there is a common 
genetic background. Indeed the current study did not find significant genetic similarities 
between asthma and COPD apart from the identification cohort and LifeLines1. As 
highlighted by the Dutch hypothesis the importance of both type and temporal sequences of 
environmental exposures contribute to the occurrence of either phenotype. This may have 
affected the phenotypic outcome considerably and hence a crude covariate adjustment may 
represent an underestimated challenge to identify common genetic determinants of asthma 
and COPD. Finally, our study has power to identify strongly prevalent SNPs, yet not rare 
variants that may have an impact on asthma and COPD. Our findings either suggest that 
there is no common genetic component in asthma and COPD or, alternatively, different 
environmental factors, like lifestyle and occupation in different countries and continents 
may have obscured the genetic common contribution.
Recent efforts to characterize substantial number of patients diagnosed with both asthma and 
COPD [41] show the increasing scientific interest in the phenotypic overlap between asthma 
and COPD. Future studies on the underlying genetics in this group of overlap patients would 
be of interest, specifically comparing outcomes with our results. Overall, our results may 
suggest a role of the NFκβ pathway, a key transcription factor in the inflammatory response, 
in both asthma and COPD, suggesting that the Dutch hypothesis may have some validity. 
However, we could not replicate associations in both asthma and COPD in most replication 
cohorts, thus this could refute the genetic background that the Dutch hypothesis implied to 
be common in asthma and COPD. Further studies including lifelong lifestyle factors across 
all cohorts need to be performed to assess whether this approach elucidates a common 
genetic background of asthma and COPD. Since none of the SNPs reached genome-wide 
significance further investigation of the loci should be performed to assess their role in both 
asthma and COPD. Although inflammatory processes differ in asthma and COPD, they are 
unequivocally mediated by NFκβ, and as suggested by our current results, they could be 
driven by the same underlying genes, COMMD10 and DDX1. Our eQTL studies support a 
functional role of COMMD10, since we established that two SNPs, therefore the natural 
next step is to perform genome-wide epistatic analysis in large cohorts of asthma and COPD 
patients to reveal the complex nature of interactions between SNPs and loci and their impact 
on the ultimate phenotype.
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Refer to Web version on PubMed Central for supplementary material.
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This article provides suggestive evidence, but not firm evidence that there is overlap in 
genetics of asthma and COPD.
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Regional association plots for DDX1, COMMD10 and GNG5P5 loci.
The plots were generated using R and regional association plot script from BROAD institute
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Forest plots of the three top SNPs in the meta-analysis of the asthma and COPD cohorts.
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eQTLs identified for COMMD10 SNPs.
Left panel: blood eQTLs, right panel: lung eQTLs. Order on x-axis is from non-risk 
homozygote, heterozygote and risk homozygote for all three eQTLs. Note: in lung tissue 
dataset, the risk homozygotes were not present.
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Gene enrichment plot using DDX1 and COMMD10 genes as a query
Smolonska et al. Page 20





































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Eur Respir J. Author manuscript; available in PMC 2014 November 03.
